Korean J Med.  2014 Oct;87(4):501-504. 10.3904/kjm.2014.87.4.501.

Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib

• Cho M
• Shim H
• Park MR

• KMID: 2269229
• DOI: http://doi.org/10.3904/kjm.2014.87.4.501

Abstract

We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib.

Keyword

Sunitinib; Hypoglycemia; Metabolic encephalopathy

MeSH Terms

Brain Diseases, Metabolic
Carcinoma, Renal Cell*
Coma*
Diabetes Mellitus, Type 2
Humans
Hypoglycemia
Protein-Tyrosine Kinases
Protein-Tyrosine Kinases